Another study has indicated that the use of galectin-3 inhibitors can block the binding of galectin-3 to EGFR, thus inhibit the galectin-3/EGFR/Akt/FOXO3 axis and inhibit the occurrence and development of pancreatic cancer in vivo and in vitro [37]. The gene discussed is FOXO3; the disease is pancreatic neoplasm.